ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2019年04月05日 10時00分
Source:
Eisai
エーザイ、シリーズ初の医薬部外品「トラベルミン(R)サポート」新発売
"乗りもの酔い、気分不快に" コンビニエンスストアで買える乗り物酔い対策品
東京, 2019年04月05日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、トラベルミン(R)シリーズから、初めての医薬部外品としてコンビニエンスストアなどでお買い求めいただける口中清涼剤「トラベルミン(R)サポート」を4月8日(月)に全国で新発売します。
「トラベルミン サポート」は、乗りもの酔い、気分不快にお使いいただける、植物由来成分カンゾウエキス主配合の医薬部外品です。お子様が服用しやすいドロップタイプで、スーッとするサイダー風味です。1粒ずつの個包装なので使いやすく、持ち運びにも便利な、5才以上の小児から大人の方まで服用できる製品です。
乗り物酔い薬を買い忘れて、旅行中に入手できずに困ったという声が多く聞かれたことから、コンビニエンスストアなどでもお買い求めいただける医薬部外品として製品化いたしました。
1952年に発売された「トラベルミン(R)」のほか、酔ってからでも効くドロップタイプの「トラベルミン(R) チュロップ」(第2類医薬品)や眠気の比較的少ない成分配合の「トラベルミン(R) R」(第2類医薬品)など、トラベルミンシリーズは、医薬品の乗り物酔い止めのナショナルブランドとして広く親しまれてきました。このたび、トラベルミンシリーズに医薬部外品の新製品「トラベルミン サポート」を加えることにより、旅先で乗りもの酔いや気分不快の症状に不安を感じる方に貢献するとともに、今後も生活者の皆様の楽しい旅行をサポートしてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2019/news201923.html
概要:エーザイ株式会社
詳細はwww.eisai.co.jpをご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Approval in Principle (AiP) for the Basic Design of a Large Ammonia-Fueled Ammonia Carrier Obtained from Classification Society
Mar 14, 2025 18:37 JST
Toyota Launches All-New Crown Estate in Japan
Mar 14, 2025 17:22 JST
Hokkaido Electric Power Corporation and Mitsubishi Corporation Establish a Joint Venture "Hokkaido Renewable Energy Aggregation Co., Ltd."
Mar 13, 2025 13:26 JST
Lexus Presents the World Premiere of the New "RZ"
Mar 12, 2025 17:45 JST
MHIET Achieves Rated Operation of a 6-Cylinder 500kW-class Hydrogen Engine Generator Set
Mar 12, 2025 14:11 JST
MOL and Fujitsu leverage AI for efficient crew replacement planning
Mar 12, 2025 13:53 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Develops Miniaturized Micro Profile, a Next-Generation Contact tape for Fifth-Generation Signal Relays
Mar 12, 2025 11:00 JST
JCB Now Available on Google Play in Thailand, Indonesia, Vietnam, Philippines, and Hong Kong
Mar 12, 2025 11:00 JST
JCB Announced Premier Sponsorship for the 10th Edition of Sakura 2025 at Singapore's Gardens by the Bay
Mar 11, 2025 18:00 JST
Hitachi Energy invests additional $250 million USD to address global transformer shortage
Mar 11, 2025 17:49 JST
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
Mar 10, 2025 20:24 JST
CEPI funds Nagasaki University to develop innovative vaccines using Nanoball platform and NEC's AI
Mar 10, 2025 12:10 JST
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 07, 2025 16:24 JST
NEC improves the energy efficiency and floor space density of 5G Mobile Core systems
Mar 06, 2025 13:20 JST
Unmanned Aerial Vehicles Being Developed by MHI Used in Demonstration of Automated Transport and Unloading of Heavy Cargo in Disaster Areas
Mar 05, 2025 16:11 JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
Mar 05, 2025 09:09 JST
MHI-MS Completes Domestic Development of Vehicle Transport Robot
Mar 04, 2025 19:39 JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
Mar 04, 2025 17:22 JST
Prideone Entertainment announces concept for post-war film to mark 80th anniversary of the end of World War II
Mar 04, 2025 16:00 JST
NTT and DOCOMO Successfully Demonstrates On-Demand Unified Control of Computing Services Through Network and Service Integration
Mar 03, 2025 20:25 JST
More Latest Release >>
Related Release
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
3/10/2025 8:24:00 PM JST
Eisai: Update on the Co-Promotion of the Oral Antifungal Agent Nailin Capsules 100mg in Japan
3/5/2025 9:09:00 AM JST
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia
3/4/2025 5:22:00 PM JST
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
3/3/2025 3:41:00 PM JST
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease
3/3/2025 1:53:00 PM JST
Eisai Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone
2/28/2025 12:31:00 PM JST
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
2/20/2025 1:29:00 PM JST
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
2/14/2025 12:09:00 PM JST
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
2/3/2025 5:23:00 PM JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
More Press release >>